Antonio
Montoto Marqués
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (1)
2024
-
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Spinal Cord, Vol. 62, Núm. 8, pp. 454-467